EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer

Yoline Lauwers iD, Timo W M De Groof, Cécile Vincke, Jolien Van Craenenbroeck, Neema Ahishakiye Jumapili, Romina Mora Barthelmess, Guillaume Courtoy, Wim Waelput, Tessa De Pauw iD, Geert Raes iD, Nick Devoogdt iD, Jo A Van Ginderachter iD

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2409668121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Yoline Lauwers und 11 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Therapy Research Group, Vrije Universiteit Brussel, Brussels 1090, Belgium. Hauptthemen laut MEDLINE: Receptors, Cell Surface, Immunotherapy, Antigens, CD, Antigens, Differentiation, Myelomonocytic. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EU/EFPIA/Innovative Medicines Initiative 2, Strategic Research Programme VUB, Fonds Wetenschappelijk Onderzoek (FWO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapies have emerged as an effective treatment option for immune-related diseases, such as cancer and inflammatory diseases. However, variations in patient responsiveness limit the broad applicability and success of these immunotherapies. Noninvasive whole-body imaging of the immune status of individual patients during immunotherapy could enable the prediction and monitoring of the patient’s response, resulting in more personalized treatments. In this study, we developed a nanobody-based immunotracer targeting CD163, a receptor specifically expressed on macrophages. This anti-CD163 immunotracer bound to human and mouse CD163 with high affinity and specificity without competing for ligand binding. Furthermore, the tracer showed no unwanted immune cell activation and was nonimmunogenic. Upon radiolabeling of the anti-CD163 immunotracer, specific imaging of CD163 + macrophages using micro-single-photon emission computerized tomography/computed tomography or micro-positron emission tomography/CT was performed. The anti-CD163 immunotracer was able to stratify immunotherapy responders from nonresponders (NR) by visualizing differences in the intratumoral CD163 + TAM distribution in Lewis lung carcinoma-ovalbumin tumor-bearing mice receiving an anti-programmed cell death protein-1 (PD-1)/CSF1R combination treatment. Immunotherapy-responding mice showed a more homogeneous distribution of the PET signal in the middle of the tumor, while CD163 + TAMs were located at the tumor periphery in NR. As such, visualization of CD163 + TAM distribution in the tumor microenvironment could allow a prediction or follow-up of therapy response. Altogether, this study describes an immunotracer, specific for CD163 + macrophages, that allows same-day imaging and follow-up of these immune cells in the tumor microenvironment, providing a good basis for the prediction and follow-up of immunotherapy responses in cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Cell SurfaceImmunotherapyAntigens, CDAntigens, Differentiation, MyelomonocyticSingle-Domain AntibodiesTumor-Associated MacrophagesAnimalsMiceHumansTumor MicroenvironmentMacrophagesPositron Emission Tomography Computed TomographyCD163 Antigen

Stichwörter der Autor:innen

CD163immuno-imagingnanobodytumor-associated macrophage

Substanzen

CD163 AntigenReceptors, Cell SurfaceAntigens, CDAntigens, Differentiation, MyelomonocyticSingle-Domain Antibodies

Autor:innen und Institutionen

  • Molecular Imaging and Therapy Research Group, Vrije Universiteit Brussel, Brussels 1090, Belgium.
  • Laboratory of Myeloid Cell Immunology, Vlaams Instituut voor Biotechnologie Center for Inflammation Research, Brussels 1050, Belgium.
  • Laboratory of Cellular and Molecular Immunology, Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels 1050, Belgium.
  • Department of Pathology, Universitair Ziekenhuis Brussel, Brussels B-1090, Belgium.
  • Laboratory of Experimental Pathology, Supporting Clinical Sciences, Vrije Universiteit Brussel, Brussels B-1090, Belgium.

ORCID-Profile: Yoline Lauwers, Tessa De Pauw, Geert Raes, Nick Devoogdt, Jo A Van Ginderachter

Förderung

  • EU/EFPIA/Innovative Medicines Initiative 2
  • Strategic Research Programme VUB
  • Fonds Wetenschappelijk Onderzoek (FWO)

Zitieren

APA

Lauwers, Y., De Groof, T. W. M., Vincke, C., Van Craenenbroeck, J., Jumapili, N. A., Barthelmess, R. M., Courtoy, G., Waelput, W., De Pauw, T., Raes, G., Devoogdt, N., & Van Ginderachter, J. A. (2024). Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2409668121

Vancouver

Lauwers Y, De Groof TWM, Vincke C, Van Craenenbroeck J, Jumapili NA, Barthelmess RM, et al. Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2409668121

BibTeX
@article{Lauwers2024,
  author = {Lauwers, Yoline and De Groof, Timo W M and Vincke, Cécile and Van Craenenbroeck, Jolien and Jumapili, Neema Ahishakiye and Barthelmess, Romina Mora and Courtoy, Guillaume and Waelput, Wim and De Pauw, Tessa and Raes, Geert and Devoogdt, Nick and Van Ginderachter, Jo A},
  title = {Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2409668121}
}
Kostenlos starten →